ISAL 2019 | EVI1 alteration in AML: mechanisms, disease risk & potential targeting

Ruud Delwel

Transcription factor alterations in acute myeloid leukemia (AML) could be a key therapeutic target, as discussed here by Ruud Delwel, PhD, of the Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands. Dr Delwel discusses his group’s research into EVI1 and the mechanisms of its alteration in AML. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video